Ocuphire Pharma
Low Science / High Science, Low Risk / High Risk, Ocuphire has a little of everything, heading into a data-rich 2021. Read More.
Coverage
Blog
Latest research notes and coverage from the editorial archive.
July 26, 2020 Update
Since our last update note in January, we have initiated on three new companies; TLC (Nasdaq: TLC), Delcath Systems (Nasdaq: DCTH), and Epigenomics (FSE:…
Epigenomics AG
We believe there is tremendous upside for investors by owning Epigenomics ahead of, what we expect to be, a positive CMS reimbursement decision by…
Delcath Systems
We believe Delcath’s $50mm market cap today is a reflection of its colorful past, not its bright future. Read More.
TLC
We believe TLC can achieve a market cap of ~400mm this year based on positive TLC590 Ph2 data, and growing investor enthusiam towards the…
January 16, 2020 Update
Over the past 3-months we have initiated coverage on three companies; Xenon Pharmaceuticals (Nasdaq: XENE), ESSA Pharma (Nasdaq: EPIX), and Acasti Pharma (Nasdaq: ACST).…
Acasti Pharma
We are initiating on Acasti Pharma as a high risk investment ideas. Read More.
Xenon Pharma
We believe through clinical success with their lead assets, XEN496 and XEN1101, Xenon can achieve a market cap of >$1 billion by 2021, reflecting…